Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Umeå University
With
Sahlgrenska University Hospital
AstraZeneca
To investigate the mechanisms underlaying the diabetes-preventing effect of candesartan with respect to possible impact on insulin sensitivity, beta cell function and adipose tissue function and distribution. For this purpose comparisons will be performed with hydrochlorothiazide and placebo treatment. It is hypothesized that candesartan will improve insulin sensitivity as compared to hydrochlorothiazide and possibly also in comparison with placebo and that this could be explained by altered fat tissue function or distribution or by an altered sympathetic to parasympathetic balance in the autonomic nervous system. Hydrochlorthiazide is chosen as comparator because thiazides are a recommended firs-line therapy in hypertension. This drug class has some detrimental effects on glucose tolerance and in insulin sensitivity.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female 18-70 years old
Diagnosed hypertension and abdominal obesity (waist circumference greater than or equal to 102 cm (M) or 88 cm (F)
You may not be if
Uncontrolled hypertension
Treatment with more than two concomitant antihypertensive medications
Diabetes Mellitus
Other endocrine disorder
Severe liver disease
Severely reduced renal function
Malignant disease
Alcohol or drug abuse
Severe psychiatric illness
History of stroke, myocardial infarction, unstable angina pectoris, participation in another clinical trial less than two months prior to screening visit
treatment with anti-obesity drugs
anti-inflammatory drugs or immunosuppressive drugs
Clareo Health | Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo